AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01259128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 Nasal Spray 500 ng/day
Description: SER120 Level 1
Study NCT03311893 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: natural orifice surgery
Description: evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
Study NCT03216213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy
Study NCT03216213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
Study NCT01259128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 nasal spray 750 ng/day
Description: SER120 (750 ng/day)
Study NCT02981017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine Intestinal submucosal xenograft
Description: Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
Study NCT03711110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive cardiovascular monitoring
Description: Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study.
Study NCT03711110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria
Study NCT04351685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial
Study NCT04351685 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG SII
Description: Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection
Study NCT04447209 — intervention group
Intervention type: OTHER
Intervention: Dietary counselling on Food Groups according to IYC Feeding practices, WHO
Description: Monitoring of Dietary diversity and growth
Study NCT01721434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Study NCT01721434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar coloured placebo
Study NCT03960398 — intervention group
Intervention type: DRUG
Intervention: Iatrogenic disease impact on emergency consultations
Description: Determination of the proportion of emergency consultations linked to iatrogenic diseases
Study NCT04181255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf
Description: This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
Study NCT04181255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
Study NCT00749749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
Description: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
Study NCT02730442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of F901318 intravenously
Study NCT00749749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ON-Q PainBuster Post-op Pain relief System
Description: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
Study NCT02138006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Description: Mealtime insulin (Actrapid) Basal insulin (Monotard)
Study NCT02138006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin treatment
Description: Insulin Mixtard
Study NCT04022616 — intervention group
Intervention type: OTHER
Intervention: Specimen collection
Description: Specimens are obtained from patients who are being treated for breast malignancies.
Study NCT02229019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer mealtime assistance
Study NCT03593213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.
Study NCT02730442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral administration
Study NCT00028561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00028561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00028561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00028561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00118729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X Aqueous Nasal Spray
Study NCT02243293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet
Study NCT02243293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet
Study NCT02208219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-supported Therapy
Description: A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
Study NCT02208219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based Music-supported Therapy
Description: A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
Study NCT02208219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements.
Study NCT02896946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted nuclear magnetic resonance imaging
Description: All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
Study NCT02838667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care plus Nephrology Care
Study NCT01766102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative Mammography
Description: The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
Study NCT01320111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Sorafenib
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day
Study NCT01320111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
Study NCT02243293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 co-formulated ABT-530
Study NCT03794791 — intervention group
Intervention type: BEHAVIORAL
Intervention: education
Description: Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
Study NCT03794791 — intervention group
Intervention type: BEHAVIORAL
Intervention: no education
Description: Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
Study NCT04660955 — intervention group
Intervention type: OTHER
Intervention: No Intervention - Observational study with MRI
Description: 90 minute MRI of the knees
Study NCT01675024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, Period 1
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study NCT01766102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mammography
Description: There is not an added device associated with this arm.
Study NCT01819740 — intervention group
Intervention type: OTHER
Intervention: determine the levels of the HEM substance in seminal plasma
Study NCT01697709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine pharmacotherapy for cannabis dependence
Study NCT01697709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study NCT01855893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auto-acupressure
Description: Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
Study NCT01855893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
Study NCT03944850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Anxiety Sensitivity Treatment
Description: CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
Study NCT01265485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coated suppository
Description: Dose escalating study
Study NCT03101800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine and Allopurinol
Description: Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
Study NCT03101800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Standard weight based azathioprine dosage
Study NCT02542618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Study NCT03416686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF star electrode electrode_Fixed)
Description: The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed).
Study NCT01018719 — intervention group
Intervention type: DEVICE
Intervention: MDCT, ECG, Echocardiography
Description: Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
Study NCT03191669 — intervention group
Intervention type: OTHER
Intervention: Auto-questionnaire
Description: Single Auto-questionnaire administered during or after a consultation/hospitalization
Study NCT02542618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Study NCT05003193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: 2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
Study NCT04219410 — intervention group
Intervention type: PROCEDURE
Intervention: Fully minimally invasive esophagectomy
Description: Esophagectomy using a novel fully minimally invasive approach
Study NCT03249363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A - Pulsed PVP-I Irrigation
Study NCT03249363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Pulsed PVP-I Irrigation
Study NCT01675024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, Period 2
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study NCT03978182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated deep rTMS
Description: A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
Study NCT02554734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104
Study NCT03978182 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: accelerated deep rTMS
Description: A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
Study NCT01258530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: over-encapsulated oseltamivir
Description: 75 mg once
Study NCT01258530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: 75 mg once
Study NCT04566822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
Study NCT04566822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
Study NCT04566822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
Study NCT01029535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid gel
Description: Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
Study NCT01891929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECOS (COgnitive REmediation for Schizophrenia)
Description: Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
Study NCT04566822 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Education Control
Description: Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
Study NCT01895491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206DNA
Study NCT01891929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (Treatment As Usual)
Description: The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
Study NCT01895491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206Ad
Study NCT02554734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa, entacapone
Study NCT01079832 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
Study NCT01079832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT04587102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body viberation
Description: vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform